Microbot Medical Inc. (NASDAQ:MBOT) Receives $6.62 Average PT from Analysts

Microbot Medical Inc. (NASDAQ:MBOT) has earned a consensus rating of “Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $6.6250.

Several analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research report on Wednesday, July 8th. Loop Capital set a $4.00 price target on shares of Microbot Medical in a report on Wednesday, June 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Microbot Medical in a research note on Tuesday, July 14th. Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Zacks Research raised shares of Microbot Medical from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 22nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MBOT. CTC Alternative Strategies Ltd. purchased a new position in Microbot Medical during the 1st quarter worth $28,000. American Century Companies Inc. purchased a new stake in shares of Microbot Medical in the 2nd quarter worth $32,000. Zacks Investment Management bought a new position in shares of Microbot Medical during the 3rd quarter worth $33,000. Man Group plc purchased a new position in shares of Microbot Medical during the fourth quarter valued at $35,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Microbot Medical during the third quarter valued at $37,000. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Trading Up 2.4%

MBOT opened at $1.94 on Tuesday. The stock has a market cap of $129.97 million, a price-to-earnings ratio of -7.44 and a beta of 1.06. The stock’s 50 day moving average price is $1.83 and its 200-day moving average price is $2.07. Microbot Medical has a one year low of $1.60 and a one year high of $4.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.30 million. On average, equities analysts forecast that Microbot Medical will post -0.28 EPS for the current year.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.